MAPT and Parkinson disease: As the earliest and most widely used inhibitor, PUGNAc has demonstrated protective effects in multiple neurodegenerative disease models: in AD models, it increases O‐GlcNAcylation of Tau protein and reduces its hyperphosphorylation, thereby slowing the decline in learning and memory functions [416]; in PD and ALS models, PUGNAc enhances neuronal activity and delays disease progression [417].